Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

69,031 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial.
Meng X, Wu T, Hong Y, Fan Q, Ren Z, Guo Y, Yang X, Shi P, Yang J, Yin X, Luo Z, Xia J, Zhou Y, Xu M, Liu E, Jiang G, Li S, Zhao F, Ma C, Ma C, Hou Z, Li J, Wang J, Wang F. Meng X, et al. Among authors: yang x, yang j. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):245-253. doi: 10.1016/S2468-1253(21)00378-2. Epub 2022 Jan 6. Lancet Gastroenterol Hepatol. 2022. PMID: 34998471 Clinical Trial.
Efficacy and safety of anlotinib combined with carboplatin and pemetrexed as first-line induction therapy followed by anlotinib plus pemetrexed as maintenance therapy in EGFR/ALK wild-type advanced non-squamous non-small cell lung cancer in China: a multicenter, single-arm trial.
He Z, Yang X, Ma T, Yang Q, Zhang C, Chen Y, Wang P, D'Incecco A, Metro G, Uematsu S, Wang Q. He Z, et al. Among authors: yang q, yang x. Transl Lung Cancer Res. 2022 Aug;11(8):1657-1666. doi: 10.21037/tlcr-22-558. Transl Lung Cancer Res. 2022. PMID: 36090635 Free PMC article.
Case report: TP53 and RB1 loss may facilitate the transformation from lung adenocarcinoma to small cell lung cancer by expressing neuroendocrine markers.
Li J, Wei B, Feng J, Wu X, Chang Y, Wang Y, Yang X, Zhang H, Han S, Zhang C, Zheng J, Groen HJM, van den Berg A, Ma J, Li H, Guo Y. Li J, et al. Among authors: yang x. Front Endocrinol (Lausanne). 2022 Dec 13;13:1006480. doi: 10.3389/fendo.2022.1006480. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36583000 Free PMC article.
Therapeutic potential of esculetin in various cancer types (Review).
Liu M, Sheng Y, Guo F, Wu J, Huang Y, Yang X, Wang M, Zhang S, Li P. Liu M, et al. Among authors: yang x. Oncol Lett. 2024 May 8;28(1):305. doi: 10.3892/ol.2024.14438. eCollection 2024 Jul. Oncol Lett. 2024. PMID: 38774454 Free PMC article. Review.
69,031 results
You have reached the last available page of results. Please see the User Guide for more information.